Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.40 |
| ▸ | HSD11B2 | P80365 | 5/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1844594 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL974024 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL12579136 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL12693260 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL12696579 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL1844823 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL1844825 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL974023 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| Hydrochloric Acid SCHEMBL2823637 | 0.98 | HSD11B1 (0.39) | HSD11B1HSD11B2DGAT1THRBCYP2C9 | |
| SCHEMBL3644747 | 0.87 | HSD11B1 (0.43) | HSD11B1HSD11B2DGAT1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111793342-A | Polycarbonate composition and preparation method thereof | 金发科技股份有限公司 | 2020-10-20 | — | — | CN | claimed |
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4472995-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | disclosed |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-14 | — | — | US | disclosed |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-26 | — | — | US | disclosed |
| EP-4192812-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240270715-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-15 | — | — | US | disclosed |
| EP-4192813-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-14 | — | — | EP | disclosed |
| EP-4192814-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-07 | — | — | EP | disclosed |
| EP-1846363-A2 | ADAMANTYL DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20070179186-A1 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | ABBVIE INC. | 2007-08-02 | — | — | US | disclosed |
| US-7217838-B2 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid; fortherapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | ABBOTT LABORATORIES (US) | 2007-05-15 | — | — | US | disclosed |
| US-20070032630-A1 | Pi-conjugated molecules | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2007-02-08 | — | — | US | disclosed |
| US-20070032630-A1 | Pi-conjugated molecules | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2007-02-08 | — | — | US | disclosed |
| US-20060281773-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006074330-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006074244-A2 | ADAMANTYL DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060148871-A1 | Metabolic stabilization of substituted adamantane | ABBOTT LABORATORIES | 2006-07-06 | — | — | US | disclosed |
| US-20060149070-A1 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid, for therapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | ABBVIE INC. | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179186-A1 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | HSD17B1, HSD3B1, HSD17B2 | HSD11B1 6/4885HSD11B2 4/4885DGAT1 65/4885 |
| US-20060149070-A1 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid, for therapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | HSD17B1, HSD11B1, HSD3B1 | HSD11B1 2/4885HSD11B2 4/4885DGAT1 86/4885 |
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | HSD11B1 2284/4885HSD11B2 2395/4885DGAT1 3793/4885 |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | HSD11B1 2060/4885HSD11B2 2039/4885DGAT1 1036/4885 |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | HSD11B1 2060/4885HSD11B2 2039/4885DGAT1 1036/4885 |
| US-20060281773-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885DGAT1 111/4885 |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | HSD11B1 2060/4885HSD11B2 2039/4885DGAT1 1036/4885 |
| US-20060148871-A1 | Metabolic stabilization of substituted adamantane | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885DGAT1 793/4885 |
| US-20240270715-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | HSD11B1 2060/4885HSD11B2 2039/4885DGAT1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.